Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A Strep A vaccine formulated with an aluminum-based adjuvant (alum) is a therapeutic candidate designed to prevent infections caused by *Streptococcus pyogenes* (Group A Streptococcus). These vaccines typically employ protein subunit or peptide-based platforms, targeting the highly variable M protein or more conserved surface antigens to elicit protective neutralizing antibodies. The addition of alum (aluminum hydroxide or aluminum phosphate) serves to enhance the magnitude and duration of the immune response by creating a depot effect and stimulating pro-inflammatory pathways. Several such candidates have reached clinical trials, including multivalent M protein vaccines (such as the 30-valent StreptAnova) and conserved peptide conjugates (such as J8-DT and MJ8), aiming to address the global burden of GAS-related diseases such as pharyngitis, impetigo, and life-threatening sequelae like rheumatic heart disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on strep A vaccine + alum.